Grupo de Melanoma

Inicio | Investigación e innovación | Programas Científicos | Programa de Oncología Molecular | Grupo de Melanoma


  • Nuria Gago
  • David Olmeda

Becarios Post-doctorales

  • Adriana Sanna

Becarios Pre-Doctorales

  • Xavier Catena
  • Marta Contreras
  • Guillermo De la Vega
  • Naiara Juan
  • Sergio Oterino
  • Thelma Poluha
  • José Antonio Torres

Técnicos de Laboratorio

  • Tonantzin Guadalupe Calvo
  • Cynthia Mucientes
  • Mireia Vallespinós

Melanomas are inherently aggressive cancers for which basic and translational research have significantly improved patient prognosis. Nevertheless, clinical responses are still incomplete. The long-term goals of our Group are to identify new progression biomarkers and to validate more effective therapeutic agents. We are particularly interested in mechanisms of cellular stress that, being selectively deregulated in melanoma, define lineage-specific vulnerabilities (publications in Nature, Cancer Cell, Nature Cell Biology, Nature Communications, among others). Our laboratory has also reported the first-in-class lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma (Nature). These systems led to the identification of new mechanisms of immune resistance (Nature Medicine) and the generation of nanoparticle-based treatments (Cancer Cell, EMBO Mol Med), with derivatives now being tested in clinical trials. Our ultimate objective is to improve the management of patients with otherwise refractory metastatic melanomas.